I have found 3 companies receiving tens of millions...
from BARDA for(ARS) study in patients, same with companies AOLS and CBLI, so why then didn't PSTI get the same type of funding......?????
are we being fast tracked over these other companies for stockpiling, thanks...????
CELLERANT AWARDED $47.5 MILLION UNDER EXISTING U.S. GOVERNMENT CONTRACT TO SUPPORT DEVELOPMENT OF CLT-008.
San Carlos, CA September 11, 2014 - Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic (blood forming) stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services. The award will support the continued advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of hematopoietic sub-syndrome of Acute Radiation Syndrome (ARS). This funding is in addition to the $116.4 million committed under the two-year base period and the first option, and is part of the total obligated contract valued at $163.8 million.
This additional funding will support Cellerant's CLT-008 development program by providing funds for its randomized Phase 2 clinical trial in patients with acute myeloid leukemia (AML), and the nonclinical studies required for approval in treating ARS. If licensed by the U.S. Food and Drug Administration (FDA), the federal government could buy CLT-008 for the Strategic National Stockpile under Project Bioshield. Project Bioshield is designed to accelerate the research, development, purchase and availability of effective medical countermeasures for the Strategic National Stockpile.
